Providence Cancer Institute of Oregon | Strategic Alliance Partners

As a leading provider of cancer care in Oregon and a global leader in immuno-oncology, Providence Cancer Institute offers the latest in cancer services and research for all stages and common types of cancer. Through its research division, the Earle A. Chiles Research Institute, patients have access to state-of-the-art genomic sequencing, adoptive cellular therapies and a robust clinical research portfolio comprising early phase, investigator-initiated, cooperative group and industry-sponsored trials. Our multidisciplinary care teams partner with patients at every step of care, from prevention and diagnosis to personalized treatment plans, support services and cancer survivorship.

Learn more at www.providence.org/ORcancer.


Connect with us:

Latest from Providence Cancer Institute of Oregon

Dr Leidner on the DPV-001 Vaccine Plus PD-1 Inhibition in Metastatic HNSCC

August 19, 2024

Video

Rom S. Leidner, MD, discusses the rationale for studying DPV-001 plus PD-1 inhibition in advanced or metastatic head and neck squamous cell carcinoma.

Dr Leidner on the Multivalent Vaccine DPV-001 in Advanced or Metastatic HNSCC

August 08, 2024

Video

Rom S. Leidner, MD, discusses data for DPV-001 combined with PD-1inhibition with or without a GITR agonist in advanced or metastatic HNSCC.

Dr Leidner on the Investigation of TCR-Engineered T-Cell Immunotherapy in Solid Tumors

July 09, 2024

Video

Rom S. Leidner, MD, discusses the investigation of T-cell receptor–engineered T-cell immunotherapy for select patients with solid tumors.

Dr Fox on a Dark Matter–Containing Multivalent Vaccine in Head and Neck Cancer

May 10, 2024

Video

Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.

HR+/HER2– Metastatic Breast Cancer Treatment Developments Continue to Unfold

October 19, 2023

Article

Alison K. Conlin, MD, discusses patient characteristics that drive second-line treatment decisions for patients with HR-positive, HER2-negative metastatic breast cancer; remaining needs for patients with HR-positive, HER2-negative disease; and the evolving role of oral selective estrogen receptor degraders in patients with ESR1-mutated disease.

Dr Conlin on CDK4/6 Inhibitor Sequencing and QOL in Breast Cancer

August 11, 2023

Video

Alison K. Conlin, MD, discusses unanswered questions regarding the use of CDK4/6 inhibitors after prior progression on CDK4/6 inhibitors and quality of life considerations in patients with breast cancer.

Dr. Conlin on the Benefits of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

November 17, 2022

Video

Alison K. Conlin, MD, discusses the benefits of trastuzumab deruxtecan in HER2-low breast cancer.

Neoadjuvant Chemotherapy Elicits Necessary Responses for Organ-Sparing Surgery in Early-Stage Rectal Cancer

September 01, 2022

Article

Chemotherapy prior to transanal excision surgery demonstrated favorable responses that led to increased organ preservation rates among patients with early rectal cancer, according to findings from the phase 2 NEO trial.